帕博利珠单抗治疗复发难治性霍奇金淋巴瘤:KEYNOTE-087研究2年随访
KEYNOTE-087是一项2期研究,纳入210例复发难治性经典霍奇金淋巴瘤患者,分为三个队列。中位随访27.6个月,盲法独立中心评审的客观缓解率为71.9%(95% CI 65.3-77.9),完全缓解率27.6%,部分缓解率44.3%。中位缓解持续时间16.5个月,中位无进展生存期在完全缓解患者中未达到。治疗相关不良事件任何级别发生率72.9%,3-4级12.0%,无治疗相关死亡。
要点
- 帕博利珠单抗单药在复发难治性经典霍奇金淋巴瘤中客观缓解率达71.9%,完全缓解率27.6%。
- 中位缓解持续时间16.5个月,完全缓解患者中位无进展生存期未达到。
- 治疗相关不良事件可控,3-4级发生率12.0%,无治疗相关死亡。
核心结论
- 帕博利珠单抗单药在复发难治性经典霍奇金淋巴瘤中具有持久的抗肿瘤活性和可控的安全性,无论既往治疗如何,包括化疗耐药患者。
研究设计与样本
- 2期KEYNOTE-087研究纳入210例复发难治性经典霍奇金淋巴瘤患者,分为三个队列:自体干细胞移植后和后续维布妥昔单抗进展(队列1);挽救化疗和维布妥昔单抗后因化疗耐药不适合移植(队列2);干细胞移植后进展但未用维布妥昔单抗(队列3)。
主要发现
- 中位随访27.6个月,盲法独立中心评审的客观缓解率为71.9%(95% CI 65.3-77.9),完全缓解率27.6%,部分缓解率44.3%。
- 所有患者中位缓解持续时间16.5个月(范围0.0+至27.0+),队列1为22.1个月,队列2为11.1个月,队列3为24.4个月。
- 完全缓解患者中位无进展生存期未达到,部分缓解患者为13.8个月(95% CI 12.0-22.1),疾病稳定患者为10.9个月(95% CI 5.6-11.1)。
- 所有患者及各队列中位总生存期均未达到。
- 任何级别治疗相关不良事件发生于153例(72.9%)患者,3级和4级发生于25例(12.0%)患者,无导致死亡的不良事件。
临床怎么用
- 帕博利珠单抗单药可作为复发难治性经典霍奇金淋巴瘤的治疗选择,包括化疗耐药和不适合移植的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Programmed death-1 inhibitors are approved for patients with relapsed or refractory classic Hodgkin lymphoma (RRcHL). We present the 2-year follow-up of the phase 2 KEYNOTE-087 study of pembrolizumab in 210 patients, based on HL progression after autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV; cohort 1); salvage chemotherapy and BV, with ineligibility for SCT owing to chemorefractory disease (cohort 2); and progression after SCT without BV (cohort 3). With a median follow-up of 27.6 months, the objective response rate (ORR) by blinded independent central review was 71.9% (95% CI, 65.3-77.9), the complete response rate (CRR) was 27.6%, and the partial response (PR) rate was 44.3%. Median duration of response was 16.5 months (range, 0.0+ to 27.0+ [+, no progressive disease at last assessment]) in all patients, 22.1 months in cohort 1, 11.1 months in cohort 2, and 24.4 months in cohort 3. Median progression-free survival was not reached in all patients with CR: 13.8 months (95% CI, 12.0-22.1) for patients with PR and 10.9 months (95% CI, 5.6-11.1) for patients with stable disease. Median overall survival was not reached in all patients or in any cohort. Treatment-related adverse events (TRAEs) of any grade occurred in 153 (72.9%) patients; grades 3 and 4 occurred in 25 (12.0%) patients; none resulted in death. Results confirmed effective antitumor activity, durability of response, and manageable safety of pembrolizumab monotherapy in RRcHL, regardless of prior treatment and including chemoresistant cHL. This trial was registered at www.clinicaltrials.gov as #NCT02453594.
引用
- Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019. PMID: 31409671. doi:10.1182/blood.2019000324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。